Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Read original reporting ↗Markets
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Read original reporting ↗No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →